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Protocol
AbstrACt
Introduction The introduction of biological disease-
modifying antirheumatic drugs (bDMARDs) has improved 
the treatment of inflammatory rheumatic diseases 
dramatically. However, bDMARD treatment failure occurs 
in 30%–40% of patients due to lack of effect or adverse 
events, and the tools to predict treatment outcomes in 
individual patients are currently limited. The objective of 
the present study is to identify diagnostic, prognostic and 
predictive biomarkers, which can be used to (1) diagnose 
inflammatory rheumatic diseases early in the disease 
course with high sensitivity and specificity, (2) improve 
prognostication or (3) predict and monitor treatment 
effectiveness and tolerability for the individual patient.
Methods and analysis The present study is an 
observational and translational open cohort study with 
prospective collection of clinical data and biological 
materials (primarily blood) in patients with inflammatory 
rheumatic diseases treated in routine care. Patients 
contribute with one cross-sectional blood sample and/
or are enrolled for longitudinal follow-up on initiation of a 
new DMARD (blood sampling after 0, 3, 6, 12, 24, 36, 48, 
60 months of treatment). Other biological materials will be 
collected when accessible and relevant. Demographics, 
disease characteristics, comorbidities and lifestyle 
factors are registered at inclusion; DMARD treatment 
and outcomes are collected repeatedly during follow-up. 
Currently (July 2017), >5000 samples from approximately 
3000 patients have been collected. Data will be analysed 
using appropriate statistical analyses.
Ethics and dissemination The protocol is approved 
by the Danish Ethics Committee and the Danish Data 
Protection Agency. Participants give written and oral 
informed consent. Biomarkers will be evaluated and 
published according to the Reporting Recommendations 
for Tumour Marker (REMARK) prognostic studies, 
Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) and the Standards for Reporting 
of Diagnostic Accuracy (STARD) guidelines. Results will 
be published in peer-reviewed scientific journals and 
presented at international conferences.
trial registration number NCT03214263.
IntroduCtIon 
Rheumatoid arthritis (RA), psoriatic arthritis 
(PsA) and axial spondyloarthritis (AxSpA) are 
examples of chronic inflammatory rheumatic 
diseases characterised by pain, disability and 
progressive decrease in workability, and are 
associated with comorbidity and risk of early 
death.1 2 The impact of these chronic diseases 
on the patients should be minimised through 
early diagnosis followed by targeted therapy 
with minimal side effects. If and when remis-
sion is achieved, the patient has the poten-
tial to maintain a life with few restrictions—a 
desirable outcome both for the patient and 
for society.
strengths and limitations of this study
 ► Nationwide collection of biological materials and 
corresponding extensive clinical data provides the 
opportunity to discover and/or validate a wide range 
of diagnostic, prognostic and predictive biomarkers 
in patients with inflammatory rheumatic disease.
 ► Recruitment of patients treated in routine care 
is expected to provide valuable data on ‘real-life 
patients’ (eg, elderly patients with comorbidities), 
which are different from the more homogeneous 
patient population in randomised controlled trials.
 ► Standardised collection of samples and quality 
control ensures comparability between samples 
from different departments, and enables research in 
less common rheumatic diseases.
 ► Patient recruitment and follow-up in routine care and 
across several rheumatic diagnoses and treatments 
will be associated with some limitations in clinical 
and biological data.
 ► The non-randomised study design inherits a risk of 
confounding and thorough statistical analysis and 
confounder adjustment is therefore important.
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The medical treatment of inflammatory rheumatic 
diseases has improved dramatically during the last 
decades. This is mainly due to an increased acknowl-
edgement of the treat-to-target concept with conven-
tional synthetic disease-modifying antirheumatic drugs 
(csDMARDs) in RA, which implies strict monitoring and 
aggressive treatment strategies with add-on or switching 
of therapy according to clinical response or side effects.3–5 
Furthermore, the biological DMARDs (bDMARDs), 
for example, tumour necrosis factor alpha inhibitors or 
other specific modulators of inflammatory signal trans-
duction, have improved outcomes for patients otherwise 
refractory to treatment with csDMARDs.4 New treat-
ment modalities including targeted synthetic DMARDs 
(tsDMARDS, eg, Janus kinase (JAK) inhibitors) are being 
introduced, and the first biosimilar bDMARDs have been 
marketed. bDMARDs and JAK inhibitors are expensive, 
and treatment failure, defined as lack of effect or serious 
adverse events, occurs in 30%–40% of patients treated 
with bDMARDs.6 7 Tools to predict treatment outcomes 
and side effects in the individual patient are currently 
limited.8
In 1998, the National Institutes of Health Biomarkers 
Definitions Working Group defined a biomarker as 
‘a characteristic that is objectively measured and eval-
uated as an indicator of normal biological processes, 
pathogenic processes or pharmacological responses to a 
therapeutic intervention’.9 10 Biomarkers are divided in 
three categories: (1) diagnostic biomarkers, which may 
be used for early diagnosis of a given disease.11 12 The 
ideal diagnostic biomarker should establish the correct 
diagnosis with high sensitivity and specificity; (2) prog-
nostic biomarkers, which correlate with specific clinical 
outcomes, and thus progression of disease, regardless of 
any treatment and (3) predictive biomarkers, which may 
be used to predict whether a given patient may benefit 
from a given treatment.13 14 Hence, biomarkers may be 
promising tools to personalise the treatment of patients 
with inflammatory rheumatic disease. Biomarkers in 
blood and tissue include a wide range of molecules with 
different characteristics such as DNA, RNA, microRNA 
(miRNA), proteins and metabolites. Genetic variation can 
be caused by single nucleotide polymorphisms (SNPs), 
nucleotide insertions/deletions and copy number varia-
tions, among which the SNP and insertions/deletions are 
the most common types of genetic variation.15–19 miRNAs 
are small single-stranded, endogenous, non-coding RNAs 
(18–25 nucleotides) and play essential roles in regulating 
gene expression, cell development, differentiation and 
proliferation.19–21 The human proteome constitutes all 
expressed human proteins and reflects the biological 
activity of the patient, and proteomics is increasingly 
used to investigate treatment response22 23 or to stratify 
responding versus non-responding patients.24 25 The 
metabolome is defined as the complete set of metabo-
lites <1500 Da found in a given biological sample. It is 
a dynamic entity, which reflects the interaction between 
the individual genetic background and factors such as 
pathophysiological conditions, diet and pharmacological 
treatment.26 In patients with RA, PsA and AxSpA, these 
biomarkers may be related to the disease itself, the asso-
ciated inflammation or treatment-related pharmacoki-
netics. Biomarkers can be detected in peripheral blood, 
synovial fluid, circulating cells or cell-free DNA in plasma 
or in tissue (eg, cartilage, bone and synovial membrane).
Currently, some biomarkers are used as part of the 
classification of arthritis patients, for example, IgM 
rheumatoid factor (IgM-RF), cyclic citrullinated protein 
antibodies (anti-CCP), C reactive protein (CRP) and 
human leucocyte antigen B27 (HLA-B27).27–29 However, 
for individual patients, these few biomarkers cannot 
differentiate a patient from a healthy subject with high 
specificity or predict mild versus severe disease. Radio-
graphical imaging is used routinely to assess cumulated 
joint damage;however, biomarkers have the potential 
of being a more feasible, specific and reproducible tool 
for both diagnostic and prognostic purposes and for the 
monitoring of treatment and disease progression.
The present protocol is an observational, prospective, 
translational research study of patients with rheumato-
logic disease followed in the nationwide Danish DANBIO 
Registry30 and the Danish Rheumatologic Biobank.31 32 
The objective is to identify new diagnostic, prognostic 
and predictive biomarkers, which can be used to (1) 
diagnose inflammatory rheumatic diseases early in the 
disease course with high sensitivity and specificity, (2) 
predict patient prognosis regardless of treatment or (3) 
predict and monitor the effective treatment for the indi-
vidual patient with minimised risk of side effects. This 
protocol has been prepared and presented according 
to the Reporting Recommendations for Tumour 
Marker (REMARK) prognostic studies and Strengthening 
the reporting of Observational Studies in Epidemiology 
(STROBE) guidelines.13 33
MAtErIAls And MEthods
study design and setting
Biological samples and clinical data are collected prospec-
tively in patients with rheumatic disease treated in routine 
care. Clinical data and outcomes are registered in the 
Danish nationwide quality registry DANBIO,30 34 and 
biological samples are collected via the Danish Rheuma-
tologic Biobank.31 32 Patient inclusion started in May 2015 
and will continue until 2025 with follow-up until 2030. If 
needed, the inclusion period can be expanded.
DANBIO is a nationwide, Danish register which serves 
as a clinical database for monitoring of clinical quality of 
treatment and which may be used for research purposes. 
DANBIO was established in year 2000 and data collec-
tion occurs prospectively by a web-based system used in 
routine care at Danish hospital Departments of Rheuma-
tology and in primary care (private practising specialists of 
rheumatology). It is mandatory to monitor patients with 
inflammatory rheumatic diseases treated with bDMARDs 
and patients with newly diagnosed RA irrespective of 
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treatment.34 Data registered in DANBIO are listed in 
the ‘Clinical data’ section below. DANBIO represents an 
excellent tool for monitoring patients in routine care and 
for research purposes.
The Danish Rheumatologic Biobank was established in 
2015 through nationwide collaboration between Depart-
ments of Rheumatology and Departments of Clinical 
Biochemistry in Denmark. The Danish Rheumatologic 
Biobank is organised according to the infrastructure 
of the well-established Danish CancerBiobank,31 and 
both biobanks are part of the Bio- and Genome Bank 
Denmark funded by Danish Regions (the governmental 
organisation who runs the public hospitals in Denmark). 
The foundation of the Danish Rheumatologic Biobank 
was funded by the Danish Rheumatism Association and 
Danish Regions. By 1  June 2017, 12 hospitals from all 
parts of Denmark (Rigshospitalet; North Denmark 
Regional Hospital; King Christian 10th Hospital for Rheu-
matic Diseases, Graasten; Aarhus University Hospital; 
Copenhagen University Hospital, Gentofte; Zealand 
University Hospital, Køge; OUH Svendborg Hospital; 
Odense University Hospital; Aalborg University Hospital; 
Hospital Lillebaelt, Vejle; Randers Regional Hospital and 
University Hospital Bispebjerg and Frederiksberg) partic-
ipated in the Danish Rheumatologic Biobank, and addi-
tional hospitals are continuously joining. Different types 
of biological material (eg, blood, tissue, synovial fluid 
and urine) are collected, handled and stored according 
to nationally approved standard operating procedures 
(SOPs)31 (see Biological samples section).
Patients contribute primarily with blood samples, but 
also other types of biological materials (synovial fluid and 
surgical tissue), when these are accessible and relevant. 
Patients contribute with one or more of the following 
Figure 1 Schematic presentation of study design and sampling strategies. Any patient diagnosed with RA, AxSpA, PsA, 
other inflammatory rheumatic disease or tissue disorder, or suspected for one of these, may participate when they meet for 
a scheduled routine clinical visit. These patients can provide one cross-sectional blood sample (A) or may be included for 
longitudinal follow-up (B) when they start treatment with a new DMARD (see text). See figure 2 for details on blood handling and 
storage. Numbers (n) indicate patients potentially eligible for inclusion in one or more of the study arms at the time of protocol 
approval. By 1 January 2018, the number of patients in DANBIO is approximately 50,000. AxSpA, axial spondyloarthritis; 
DMARD, disease-modifying antirheumatic drug; PsA, psoriatic arthritis; RA, rheumatoid arthritis. 
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samples: (1) cross-sectional blood samples: patients 
provide one cross-sectional sample when they meet for 
a scheduled routine clinical visit (figure 1A); (2) longitu-
dinal blood samples: patients may be enrolled for longi-
tudinal follow-up when they start treatment with a new 
DMARD. Switching from csDMARD to bDMARD or from 
one bDMARD to another bDMARD, indicates a new base-
line sample (figure 1B) and (3) other biological mate-
rials: patients may contribute with representative samples 
of biological material if they are scheduled for joint punc-
ture with aspiration (synovial fluid), surgery or biopsies 
(synovia, cartilage, bone, bone marrow or other tissues). 
Cross-sectional sampling may be done at any given disease 
stage and at any time point during treatment. Longitu-
dinal blood samples are collected at baseline and after 3, 
6, 12, 24, 36, 48 and 60 months of treatment. In case of 
serious adverse events or treatment withdrawal, additional 
blood sampling is performed (figure 1B). Approximately 
half of the material will be used for the present study. The 
other half can be made available to other researchers, 
who wish to cooperate, according to guidelines in the Bio- 
and Genome Bank Denmark.
The present protocol is designed to investigate a broad 
range of biomarkers in patients with inflammatory rheu-
matic diseases. One of the first longitudinal cohorts in 
the study included patients who switched from originator 
infliximab (IFX, Remicade) to biosimilar IFX (CT-P13, 
Remsima). According to national guidelines issued in 
2015, all Danish patients diagnosed with inflammatory 
rheumatic diseases (RA, PsA or AxSpA), and treated with 
originator IFX, were switched to CT-P13.35 In association 
with this non-medical switch, the aim was to investigate the 
following biomarkers and clinical outcome: (1) effects of 
the switch on serum IFX (sIFX) and presence of antidrug 
antibodies (ADAb) and (2) association between sIFX 
and ADAb at the time of switch on adherence to CT-P13 
treatment.36 Clinical data and longitudinal blood samples 
were collected as described in the present protocol.
Participants
The Biomarker Protocol is an open cohort study, that 
is, participants may enter and leave the population at 
different time points during monitoring. Patients are 
eligible for inclusion if they are followed in routine care 
and monitored in DANBIO with one of the following 
diagnoses: RA, AxSpA, PsA, other inflammatory rheu-
matic diseases or tissue disorders, or are suspected for 
one of the above. Patients must be able to give written and 
oral informed consent and be aged ≥18 years. There are 
no exclusion criteria. Patient inclusion and follow-up will 
be performed by nurses and physicians when the patients 
meet for scheduled routine clinical visits. The number 
of potentially eligible patients for the study is shown in 
figure 1.
Clinical data
At the time of inclusion, the following clinical data are 
collected in DANBIO30 34 37:
1. Patient demographics: for example, age, gender, body 
weight, diagnosis and disease duration.
2. Exposures: that is, previous and current treatment 
with corticosteroids, non-steroid anti-inflammato-
ry drugs and DMARDs, including dosing schedule, 
start and stop date and reason for treatment with-
drawal.
3. Outcomes: patient-reported outcomes (eg, Visual 
Analogue Scales for pain, fatigue, patient’s global, 
Health Assessment Questionnaire, quality of life), 
Disease Activity Score 28-joints, serum CRP concen-
tration, radiographical status (for RA: erosions on 
X-rays of hand or feet), and bone mineral density 
(BMD). In axial disease: Bath Ankylosing Spondylitis 
(BAS) scores for Disease Activity Index (BASDAI), 
Function Index (BASFI) and Metrology Index (BAS-
MI) are registered.
4. Comorbidities and lifestyle factors: serum cholester-
ol, diabetes, blood pressure, cardiovascular disease 
or other comorbidities, smoking status and exercise 
habits.
On every new collection of biological material, expo-
sure and outcome data are re-evaluated and registered 
within 30 days before/after the collection of biological 
material. Any prescription of medical treatment and the 
monitoring of disease status (radiographical status, BMD, 
etc) are done as part of routine care and do not follow a 
specific study protocol. Data registration in the DANBIO 
Registry follows DANBIO guidelines.34 37
biological samples
The collected biological material is primarily blood. Syno-
vial fluid, tissue, cartilage, bone and bone marrow may 
also be collected, when accessible and relevant. Periph-
eral blood is collected in one EDTA tube (9 mL), two 
serum tubes (2×9 mL) and one PAXgene blood RNA 
tube (2.5 mL, Becton and Dickinson, Lyngby, Denmark). 
Blood samples are processed according to the nation-
ally approved SOP for blood (figure 2).31 In brief, EDTA 
whole blood (1.5 mL) is isolated followed by the centrif-
ugation of EDTA and serum tubes at 2000xg and 4°C 
for 10 min. After centrifugation 2×2 mL EDTA plasma, 
1× EDTA buffy coat and 4×2 mL serum are isolated. 
PAXgene blood RNA tubes are kept at room temperature 
for 2–72 hours, hereafter frozen at −20°C for 24–72 hours, 
and finally stored long term at −80°C. Whole blood and 
buffy coat are stored at ≤−20°C; plasma and serum are 
stored at −80°C.
Synovial fluid is collected in EDTA tubes (9 mL) and 
centrifuged at 2000×g and 4°C for 10 min. The cell-free 
supernatant is transferred to 5 mL cryotubes and each 
cell pellet is resuspended in 1 mL supernatant and pooled 
in 5 mL cryotubes. Sample processing results in: ≤20×5 mL 
cell-free synovial fluid and ≤2×5 mL cell pellet, which are 
stored long term at −80°C.
Preanalytical factors such as date and time of sampling, 
handling and storage, temperature during transporta-
tion, and the exact handling procedure are registered in 
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the nationwide Bio- and Genome Bank Denmark registry. 
All samples are pseudonymised before storage.
Assay methods
The protocol aims to investigate the following biomarkers 
in blood, synovial fluid or tissue:
1. Genetic variation using next-generation sequencing 
and whole-genome sequencing, and RNA and miRNA 
expression profiles.
2. Protein biomarker profiles of inflammation, and 
bone  and cartilage metabolism using, for example, 
the MultiBiomarker Disease Activity score (a panel 
of 12 proteins)38 (Crescendo Bioscience, South San 
Francisco, California, USA), Proseek Multiplex pro-
tein arrays (panels of 92 proteins) (Olink Proteom-
ics, Uppsala, Sweden, www. olink. com) or proteomics 
platforms, such as mass spectrometry, protein arrays 
or multiplexed ELISA.
3. Metabolites using Nuclear Magnetic Resonance-spec-
troscopy.
4. ADAb against bDMARD and drug concentrations (eg, 
IFX) using a target-based assay fully automated on the 
AutoDELFIA (PerkinElmer, Waltham, Massachusetts, 
USA) immunoassay platform (Oslo University 
Hospital, Radiumhospitalet, Oslo, Norway).
All samples will be analysed in pseudonymised form 
to ensure blinded testing by the laboratory personnel. 
The list of specific diagnostic, prognostic and predictive 
biomarkers will be updated continuously according to 
new discoveries. The methods for biomarker analysis are 
rapidly expanding and improving, and the best available 
method will be used at time of analysis.
statistical methods
For the longitudinal samples, it is expected that the 
numbers collected during a 10-year period will provide 
sufficient statistical power to identify prognostic and 
predictive biomarkers if these are present among >10% 
of the patients. Knowledge within the field is still insuf-
ficient, thus, it is not possible to perform a comprehen-
sive power calculation; this will, however, be performed 
before any biomarker analysis is done.
In general, statistical analyses will be done according to 
available data; the following statistical tests may be used 
(the list is not complete): comparison of group demo-
graphics will be done with Student’s t-test, Pearson’s χ2 
test or Mann-Whitney U test according to the distribution 
of data. Due to the large size of the dataset the proba-
bility for type II error in testing the hypothesis will be low. 
Treatment duration and time to event can be explored 
Figure 2 Standard operating procedure (SOP) for blood handling in the Danish Rheumatologic Biobank.31 Peripheral blood is 
collected in one EDTA tube, two serum tubes and one PAXgene blood RNA tube. Serum tubes coagulate at room temperature 
for 30 min to 2 hours. From the EDTA tube, 1.5 mL whole blood is isolated. EDTA and serum tubes are centrifuged at 2000xg and 
4°C for 10 min. EDTA plasma (2×2 mL), EDTA buffy coat and serum (4×2 mL) are isolated. Processed blood samples are stored 
at ≤−20° C. PAXgene blood RNA tubes are kept at room temperature for 2–72 hours, then frozen at −20°C for 24–72 hours and 
stored at −80°C.
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with Kaplan-Meier curves, log-rank statistics and Cox 
regression analyses. Treatment outcomes across groups 
or according to specific biomarkers will be analysed with 
logistic regression analyses. Multivariable analyses will 
be performed in order to study the impact of potential 
confounders. These confounders may be identified in 
the DANBIO Registry (gender, age, smoking status or 
other baseline characteristics). All included patients are 
recruited and treated in routine care across Denmark 
and this will inevitably lead to some missing data (missing 
sampling of biological material, missing registration of 
corresponding clinical data, whenever biological material 
is collected, patient lost to follow-up, etc). For sensitivity, 
various statistical methods may be applied in order to 
test the robustness of the results. This may be done as 
last observation carried forward in case of lacking data on 
clinical outcomes, non-responder imputation or statistical 
multiple imputation of missing data. Statistical expertise 
will be included when necessary.
EthICs And dIssEMInAtIon
The Protocol is approved by the Danish Ethics Committee 
(H-2-2014-086, supplementary protocol 49419) and the 
Danish Data Protection Agency (RH-2015-297, I-suite 
04318). The Danish Rheumatologic Biobank is approved 
by the Danish Data Protection Agency (GLO-2015–6, 
I-Suite 03490). All patients receive verbal and written 
information before enrolment, and give oral and written 
consent at baseline according to the guidelines from the 
Danish Ethics Committee. All patients are informed that 
they can withdraw from the study at any time without it 
having consequences for their treatment. In case of with-
drawal, samples are discarded and all patient-related 
registrations deleted from the Bio- and Genome Bank 
Denmark registry.
The sampled volume of blood for the study is 26.5 mL 
per patient-visit and maximum 240 mL/year. The 
sampling of blood for the study is performed simultane-
ously with scheduled routine blood sampling, thus mini-
mising the discomfort for the patient. Synovial fluid, 
surgical tissue or bone marrow will only be collected if 
relevant interventions occur as part of routine care and 
surplus material, not used for diagnostic or therapeutic 
purposes, is available. The patients will be contacted 
and informed regarding the overall study results if they 
indicate interest in this in the patient study consent 
form. Direct feedback to the patient may be relevant 
in case of the discovery of mutations in known disease-
linked genes or as random discoveries, and will occur 
according to the guidelines directed by the Danish 
Ethics Committee (document no: 1293688, October 
2013). The physician in charge of the project at the 
individual department is responsible for conducting the 
study in accordance with the Declaration of Helsinki. 
Study participation does not affect the treatment course 
of individual patients and the patients will be treated 
according to clinical practise.
Due to the large number of included patients, it will 
be possible to perform exploratory as well as validation 
biomarker studies. We plan to evaluate and publish 
study results according to the REMARK,13 STROBE33 
and the Standards for Reporting of Diagnostic Accu-
racy (STARD)39 guidelines. Results will be published in 
international and peer-reviewed scientific journals and 
presented at international conferences. Negative, positive 
as well as inconclusive results will be published. If rele-
vant, collaborations with international researchers will be 
established to facilitate the right expertise for biomarker 
analyses. The first results (measurements of sIFX and 
ADAb drug levels up to 1 year after switch from originator 
to biosimilar IFX) have been presented36 37 40
study stAtus
Patient recruitment started in May 2015 and is expected 
to continue until 1 January 2025, with follow-up until 
1 January 2030. Currently, approximately 3000 patients 
have been enrolled in the study and >5000 blood samples 
have been collected.
dIsCussIon And PotEntIAl lIMItAtIons
In this observational, prospective and translational 
biomarker study of patients with inflammatory rheumatic 
diseases, blood samples are collected in routine care 
and closely linked to extensive clinical data regarding 
rheumatic disease status and activity, medical treatment, 
treatment efficacy and adverse events, and comorbidi-
ties. The study protocol allows for a large-scale collection 
of blood and other biological materials with the aim to 
identify new biomarkers that can be used for improved 
personalised treatment of patients with inflammatory 
rheumatic diseases. Additionally, the nationwide collec-
tion of biological materials and clinical data is intended 
to further promote research collaboration within inflam-
matory rheumatic diseases, both nationally and interna-
tionally, in order to ensure research of the highest quality 
for the benefit of the patients.
Positivity for IgM-RF and anti-CCP are established risk 
factors for development of RA, and they are currently 
used as part of classification criteria and as prognostic 
markers.3 In AxSpA, HLA-B27 is part of the disease classi-
fication.41 Apart from the erythrocyte sedimentation rate 
and serum-CRP level, no biomarkers are used in routine 
care, and they cannot predict treatment responses or 
side effects. The wide range of currently available and 
future bDMARDs with different modes of action for 
the treatment of inflammatory arthritis, and the recent 
introduction of biosimilars and tsDMARDS, stresses the 
importance of improved ability to select the most effec-
tive treatment in the individual patient. Development 
of diagnostic, prognostic and predictive biomarkers will 
benefit the treatment of future patients and facilitate 
personalised medicine.
 o
n
 2 August 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2017-019325 on 1 February 2018. Downloaded from 
 7Kringelbach TM, et al. BMJ Open 2018;8:e019325. doi:10.1136/bmjopen-2017-019325
Open Access
Patient recruitment and follow-up in routine care 
will lead to some limitations in clinical and biological 
data. Since patients are recruited across several rheu-
matic diagnoses and treatments, patient inclusion may 
take some time in order to obtain enough samples for 
a specific research question. However, since it is manda-
tory to register patients receiving biological treatment 
in DANBIO, coverage is high (≈96%)42 and the risk of 
selection bias low. The risks for the patient are minimal 
and are out-weighted by the benefits for future patients. 
The non-randomised study design inherits the risks 
of confounding, and thorough statistical analysis and 
confounder adjustment is therefore important. On the 
other hand, the wide recruitment of patients treated in 
routine care may provide valuable data on, for example, 
elderly patients with comorbidities. This may be a valu-
able supplement to data generated in randomised trials.
Hopefully, the results of the present study will provide 
us with new biomarkers that will improve our ability to 
(1) diagnose rheumatic diseases more accurately and at 
an earlier stage, (2) prognosticate the development of 
rheumatic diseases and (3) predict and monitor treat-
ment effectiveness in the individual patient (personalised 
treatment).
The Danish Rheumatologic Biobank provides an 
infrastructure for national and international research 
collaboration. Thus, researchers, who are interested in 
collaboration regarding samples and/or clinical data 
from DANBIO should contact the Danish Rheumatologic 
Biobank31 and DANBIO,30 respectively.
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